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During the inflammatory response, immune cells egress from the circulation and follow a chemotactic and haptotactic gradient
within the tissue, interacting withmatrix components in the stroma andwith parenchymal cells, which guide them towards the sites
of inflammation. Polarized epithelial cells compartmentalize tissue cavities and are often exposed to inflammatory challenges such
as toxics or infections in non-lymphoid tissues. Apicobasal polarity is critical to the specialized functions of these epithelia. Indeed,
a common feature of epithelial dysfunction is the loss of polarity. Herewe review evidence showing that apicobasal polarity regulates
the inflammatory response: various polarized epithelia asymmetrically secrete chemotactic mediators and polarize adhesion
receptors that dictate the route of leukocyte migration within the parenchyma.We also discuss recent findings showing that the loss
of apicobasal polarity increases leukocyte adhesion to epithelial cells and the consequences that this could have for the inflammatory
response towards damaged, infected or transformed epithelial cells.
1. Introduction
Leukocyte recruitment into the inflamed parenchyma
requires successive interactionswith cellular and stromal bar-
riers that establish mechanical, chemotactic and haptotactic
gradients to guide immune cells towards the inflammatory
focus. The first stage of this immune steeplechase, the
leukocyte transendothelial migration, is a multi-step cascade
of interactions that have been extensively studied in recent
years in different vascular beds and experimental models,
and some comprehensive reviews on this topic can be found
in this special issue [1–5]. The events that follow leukocyte
extravasation are perhaps less well characterized, although
significant advances have been made with the advent of
high-resolution intravital microscopy and the development
ofmore sophisticated culture systems to investigate leukocyte
migration and interactions in three dimensions. Particular
attention has been paid to elucidating how leukocytes can
migrate through the stroma, the way these cells remodel
their morphology and sense cues that guide them towards
dysfunctional tissue areas. These areas are often made up
of polarized parenchymal epithelial cells that form barriers
to compartmentalize functions in cavities of the liver,
intestine or lungs (Figure 1). Compared to the endothelium,
the molecular mechanisms involved in the interaction of
infiltrated or tissue-resident immune cells with parenchymal
barriers have not been so extensively studied. Polarized
epithelial barriers establish two types of interactions. On the
one hand, similar to endothelial cells, parenchymal epithelia
must guide leukocytes to traverse them in order to reach
a localized inflammatory focus, for example, in the lung
or intestinal mucosa. These interactions are thus transient
and often occur in two directions, from the parenchyma
to the lumen and viceversa [6]. On the other hand, these
barriers contain damaged or infected cells that are part of
the inflammatory focus and the endpoint of the leukocyte
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Figure 1: Endothelial and epithelial barriers determine the different stages of leukocyte migration in its journey towards the inflammatory
focus in complex tissues. The parenchymal three-dimensional organization contributes to establish an haptotactic and chemotactic gradient
(1) Leukocyte adhesion and transendothelial migration or diapedesis. (2) Exiting the vessel. Once they reach the subendothelial space,
leukocytes traverse the basement membrane and interact with pericytes, which promote the complete extravasation of immune cells via
adhesion receptors. (3) Interstitial migration. Leukocytes switch from a two-dimensional to a less adhesive three-dimensional migration
to circumvent topological constraints in the stromal barrier. Fibroblasts help leukocyte navigation by maintaining protein scaffolds and
secreting mediators such as cytokines and growth factors, which act as chemotactic cues. (4) Interaction with polarized epithelial barriers.
Following haptotactic and chemotactic gradients, leukocytes encounter polarized epithelial cells and often undergo transepithelial migration.
The polarized distribution of the adhesive and chemotactic machineries mediates leukocyte guidance through the parenchymal epithelia for
immunosurveillance or the clearance of pathogens and dysfunctional cells.
migratory journey, so some sort of footprint, which is not
completely understood, must exist in these cells to promote
a preferential adhesion with infiltrated leukocytes. So far,
most of the in vivo and in vitro approaches to study leukocyte
migration across the tissue parenchyma have addressed the
role of each single tissue barrier that immune cells encounter
in their journey to the inflammatory focus. We believe that
successfully combining our current knowledge about leuko-
cyte extravasation, three-dimensional migration through the
stroma and the sequential interactions with parenchymal
cell barriers, which include adopting unified experimental
models, will help shed light on the entire migratory route of
each immune cell type and on the specificity of the innate
inflammatory responses in each type of tissue.
2. The Long Journey towards
the Parenchymal Inflammatory Focus after
Leukocyte Transendothelial Migration:
Leaving the Vessel
Most of the leukocyte efflux from the bloodstream occurs
in postcapillary venules, small vessels covered by pericytes
and other mural cells and the basement membrane, which
are a secondary barrier that extravasating leukocytes have
to traverse [9]. Endothelial cells initiate leukocyte extravasa-
tion, but subendothelial, leukocyte-pericyte interactions are
required for the final egression of leukocytes into the intersti-
tium (Figure 1). Similar to endothelial cells, pericytes express
adhesion receptors in response to inflammatory cytokines
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and establish adhesive tracks at least in the case of neutrophils
[10]. Few studies have addressed the contribution of ablu-
minal endothelial surfaces, the basement membrane and the
pericyte barriers to leukocyte trafficking into the tissue, but
the most recent reports suggest a pro-active role for pericytes
in controlling leukocyte navigation into the parenchyma
through the intercellular adhesion molecule-1 (ICAM-1), the
counter-receptor of 𝛽2-integrins, which is expressed in per-
icytes at levels comparable to those in inflamed endothelial
cells [10–12]. This interaction occurs mainly in postcapillary
venules, where myeloid leukocytes egress through regions
between pericytes that have low density of matrix proteins
[13]. A subset of these extravasated leukocytes interacts with
pericytes surrounding capillaries and arterioles. Pericytes
in these microvessels express macrophage inhibitory factor
(MIF), which attracts fully extravasated neutrophils and
macrophages and, as a consequence, these leukocytes are
guided to sites of (sterile) inflammation [12]. Pericytes are
not the only perivascular cell type that regulates leukocyte
trafficking. Two other cell types have been shown to be
critical for neutrophil extravasation: first, resident perivascu-
lar macrophages from dermal venules are the main source
of neutrophil chemoattractants and secrete the chemokines
CXCL1, CXCL2, CCL2, CCL3, and CCL4 in an experimental
model of bacterial infection of the skin [14]; second, vessel-
associatedmast cells secrete the chemoattractants CXCL1 and
CXCL2 to induce neutrophil extravasation in a model of
intraperitoneal lipopolysaccharide (LPS) stimulation [4].
Leukocyte extravasation constitutes a transition between
a two-dimensional migration mode, in the presence of
shear stress, to a three-dimensional migration mode upon
infiltration into the connective tissue (Figure 1). Immune cells
in the interstitium interact with the extracellular matrix and
the stromal cells adopting a migratory mode called ameboid,
in which cells with a rounded morphology can easily change
shape and squeeze between matrix fibers with little stro-
mal remodeling [15]. This ameboid movement requires less
adhesiveness than two-dimensional motility, and is mainly
based on the ability of the leukocytes to reshape their
actomyosin cytoskeleton, emitting pseudopods and inducing
contractility at the rear of the cell.Within the heterogeneity of
the tissue, leukocytes usually combine adhesion-independent
and -dependent motility modes and rapidly adapt their
migratory requirements to the microenvironment of the
parenchyma [16].
Various fibroblast subtypes reside in the stroma and
are adjacent to parenchymal epithelial barriers. Pericryptal
fibroblasts, hepatic Ito cells and glomerular mesangial cells
support epithelial cell function [17, 18]. These fibroblasts
regulate tissue homeostasis and repair by secreting basement
membrane factors that contribute to the architecture of
the internal epithelial barriers and regulate epithelial cell
proliferation and differentiation [19, 20]. Stromal fibroblasts
have been attributed a role of maintaining a healthy environ-
ment in the lymphoid and non-lymphoid tissue by having
an immunomodulatory effect on neighboring endothelial
and immune cells [17, 20, 21]. Stromal fibroblasts mediate
leukocyte parenchymal navigation through damaged areas
by secreting extracellular matrix components as well as
cytokines, chemokines and growth factors as soluble chemo-
tactic cues. Direct fibroblast-leukocyte interactions have been
investigated in the context of allergic, inflammatory and
cancer pathologies [22, 23]. Fibroblasts from patients with
rheumatoid arthritis can present autoantigens to infiltrated
T-cells and, reciprocally, these cells can induce a proinflam-
matory status in the fibroblast-like synoviocytes [24, 25].
A probably aberrant leukocyte-fibroblast interaction also
occurs in systemic sclerosis, a disease of unknown etiology,
in which immune cells cause fibrosis by inducing collagen
synthesis in skin fibroblasts [26]. However, the main role
of tissue fibroblasts in leukocyte migration seems to be the
maintenance of the stromal protein scaffolds and the secre-
tion of mediators that attract or activate migrating immune
cells. In conclusion, leukocytes not only follow chemotactic
and haptotactic cues within the vessel. The parenchyma
establishes a full program of immune cell guidance towards
the inflammatory focus. Many cell types orchestrate this
program either directly, by interacting with leukocytes, or
indirectly, by secreting mediators and extracellular matrix
components.
3. Reaching the Polarized Epithelia in
the Parenchyma
In several tissues, parenchymal cells need to establish lumens
to perform specialized functions, including filtration, absorp-
tion, secretion and protection. Polarized epithelia and the
underlying basement membranes form different mucosal,
blood-brain, bile duct or renal barriers, which are exposed
to internal cavities and are therefore prone to infections and
intense mechanical, toxic and inflammatory stresses. The
compartmentalization properties of epithelial barriers arise
from the ability to polarize and form intercellular junctions
that separate apical from basolateral membrane domains.
Columnar epithelial cells place their apical domains facing
the lumens that form relatively large tube-shaped cavities
[27]. Other polarized epithelia, such as hepatocytes, form
smaller apical lumens between adjacent cells, giving rise to
smaller tubules that form the bile canaliculus, an intricate
network of channels that drains bile into the bile ducts
and eventually into the intestine [28]. Importantly, as we
shall see below, the compartmentalization properties of the
parenchymal epithelia are also fundamental for controlling
immune cell trafficking.
Resident leukocytes traverse parenchymal epithelial bar-
riers to survey luminal surfaces exposed to extra-tissular
material [29, 30]. Epithelial cell dysfunction can also produce
an inflammatory response and additional leukocyte infiltra-
tion. Such infiltration may have the final aim of reaching
internal cavities, such as the intestinal lumen, to fight luminal
pathogens, but leukocytes may also interact with dysfunc-
tional epithelia that themselves constitute the inflamma-
tory focus. Hence, immune cells preferentially contact with
impaired epithelial cells to eliminate or receive information
from them, so mechanisms must exist to help leukocytes
discriminate in the same inflammatory microenvironment
between sick cells and inflamed, but still-operative, adjacent
cells. On the other hand, leukocytes, particularly neutrophils
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in the intestine, play an important role in the resolution
of epithelial inflammation. Neutrophils transmigrate across
inflamed epithelial monolayers and release factors that con-
tribute to tissue repair. It is therefore critical to understand
the signals that mediate the leukocyte-epithelium interaction
in diverse physiological and pathological scenarios (Figure 1).
4. Polarized Secretion of Signals Involved in
Leukocyte Attraction to Epithelia
The remarkable compartmentalization occurring between
apical and basolateral environments in polarized epithelia led
researchers to hypothesize that leukocyte chemoattractants
are released in a polarized way. IL-8 is one of the main
chemokines driving leukocyte infiltration into the intestine.
In an in vitro model of human intestinal epithelial cells,
Sonnier and colleagues, elegantly showed the different effects
on IL-8 secretion caused by polarized TNF𝛼 stimulation.
Whereas basolateral TNF𝛼 stimulation resulted in secretion
of IL-8 from both apical and basolateral membrane regions,
apical stimulation induced the secretion of IL-8 exclusively
from these surface domains. By combining blocking anti-
bodies, the authors proposed that the receptor 2 for TNF𝛼
(TNFR2) is apically confined and responsible for polarized
IL-8 secretion [31]. Interestingly, the IL-8 receptor CXCR1
is also apically distributed in these cells, suggesting the
existence of an autocrine pathway for this chemokine on the
luminal side of the intestinal epithelium [32]. Other polarized
epithelia, such as endometrial epithelial cells, also vectorially
secrete IL-8 depending on the membrane domain receiving
the inflammatory stimulus [33]. These cells also release other
inflammatorymediators from the apical surfaces such as IL-6
or prostaglandins [33, 34].
The polarized secretion of inflammatory mediators is
probably defined by the cell type and the nature and location
of the stimulus that induces secretion; indeed, the secretion of
IL-8 and other CXC chemokines has been found to be pref-
erentially basolateral in other polarized epithelial beds and
with other pathogen-derived stimuli [35–38]. Chemokine
secretion polarity has been investigated in more detail with
IL-8, but other chemokines involved in lymphocyte attrac-
tion to intestinal epithelia, such as interferon 𝛾–inducible
protein (IP)-10, monokine induced by interferon 𝛾 (MIG)
and MDC/CCL22, are basolaterally secreted and have a
differential effect in the basolateral and apical milieu, attract-
ing lymphocytes preferentially from epithelial basolateral
membranes, at least for CCL22 [39, 40].
Chemokines are not the only polarized parenchymal
chemoattractants. The eicosanoid Hepoxilin A3 (HXA3)
is a proinflammatory lipid that is also selectively released
from the apical membrane domains of polarized epithelia in
intestine and lung. In these two organs, HXA3 is a potent
neutrophil chemoattractant that follows the effect of IL-8 to
promote neutrophil transepithelial migration [41, 42]. The
mechanisms regulating the polarized secretion of this lipid
mediator are not well understood, but the apical epithe-
lial marker, multidrug-resistance associated transporter 2
(MRP2) is clearly involved in the apical secretion of HXA3
in the intestine. HXA3 and MRP2 are both induced in
experimental models of chronic intestinal inflammation and
so constitute a potential therapeutic target [43]. In conclu-
sion, the apicobasal polarity of these chemoattractants is
important for efficient leukocyte guidance towards different
physiological or pathological inflammatory foci within the
complex three-dimensional organization of tissues.
5. Apicobasal Polarity of Adhesion
Receptors Involved in Leukocyte-Epithelial
Cell Interactions
The leukocytes chemoattracted by parenchymal epithelial
cells finally make contact. Leukocytes first encounter basolat-
eral epithelial membranes containing fucosylated proteogly-
cans that can interact with 𝛽2 integrins [44]. This binding is
often the initial step in the process of leukocyte transepithelial
migration. It has been reported that macrophages traverse
retinal-pigmented epithelial cells from diabetic rats through
caveolin-1-positive transcellular pores [45], similar to those
found in the transcellular diapedesis of vascular endothelial
cells [46, 47]. However, this route of transmigration has not
been observed in other polarized epithelial beds. Since tran-
scellular transmigration occurs in the areas of lower mem-
brane resistance [48] the columnar shape that many of the
polarized epithelial barriers acquire probably makes it very
difficult for immune cells to break through single epithelial
cells. Thus, immune cells preferentially negotiate epithelial
transmigration following a paracellular route between two
cells. The receptor from the immunoglobulin superfamily
CD47 is located at lateral cell surfaces and interacts with the
signal regulatory protein-(SIRP)-𝛼 from at least neutrophils,
macrophages and dendritic cells [49–51] thereby mediating
basolateral-to-apical transepithelial migration. The interac-
tion of these pair of molecules inhibits phagocytosis between
immune and cancer cells [51], so these molecules may well
regulate the stability of leukocyte-epithelial cell interactions
to promote the leukocyte movement across the barrier from
the basolateral side. CD47 is also expressed in leukocytes
and associates with and regulates their integrin machinery
[52]. However, a possible function of CD47 in modulating
leukocyte integrin activation from the epithelium has not
been reported.
Similar to endothelial cells, some surface receptors
forming epithelial cell-cell junctions play a dual role and
mediate the process of paracellular transepithelial migration
by guiding immune cells across the boundaries between
two epithelial cells. Of these, junctional adhesion molecules
(JAMs) are paradigmatic receptors from the immunoglobulin
superfamily that switch between epithelial cell-cell junctions
to heterotypic interactions between endothelial or epithe-
lial cells and leukocytes. The intestinal epithelium mainly
expresses JAM-A, JAM-C, JAM4, Coxsackie virus and aden-
ovirus receptor (CAR) and the more distantly related CAR-
like membrane protein (CLMP) [53]. It has been reported
that the interaction of desmosomal JAM-C with 𝛽2-integrins
mediates PMN transepithelial migration [54]. Desmosomes
are more basolaterally located than tight junctions, so
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this interaction probably precedes that established between
epithelial CAR and JAM-L expressed in neutrophils, which
also participates in the leukocyte transepithelial migration
[53, 55]. In contrast, JAM-Ahelpsmaintain the integrity of the
epithelial monolayer but does not seem to mediate leukocyte
crossing of polarized epithelia [56, 57].
PMNs also proactively contribute to open paracellular
spaces during transmigration by secreting serine-proteases
such as elastase and cathepsin G.These serine-proteases acti-
vate basolateral epithelial protease-activated receptor (PAR)-
1 and -2 [58]. PARs are G-protein coupled receptors, which
are activated by the proteolytic cleavage of their extracellular
domain [59]. Active PARs induce actomyosin-mediated con-
traction and transiently reduce barrier function to facilitate
the transepithelial passage of the immune cell [58].
In summary, the first polarized molecular complexes
that leukocytes find during their abluminal interactions with
the polarized epithelium are those localized mostly in the
lateral cell-to-cell junctions, which play a double function
maintaining the epithelial barrier function and facilitating the
transmigration of immune cells.
6. The Apical Adhesion Machinery
Once leukocytes interact with the epithelial protein machin-
ery exposed in the basolateral domains and traverse the
epithelial monolayer, they encounter adhesion proteins con-
fined in the epithelial apical membrane domains. The
intercellular adhesion molecule (ICAM)-1 belongs to the
immunoglobulin superfamily of transmembrane receptors
and interacts with 𝛽2 integrins from immune cells. Unlike
other adhesion receptors that are selectively expressed in
endothelial cells, such as E-selectin or VCAM-1, ICAM-1 is
broadly expressed in different cell types upon proinflam-
matory stimulation, including pericytes and parenchymal
epithelia. In polarized epithelia, the stimulation of human
intestinal epithelial cells with IFN𝛾 or by exposure to
enteropathogenic bacteria increases apical ICAM-1, suggest-
ing that luminal adhesion of immune cells is important for
the inflammatory response to gastrointestinal pathogens [8,
60, 61]. Apical ICAM-1 promotes neutrophil adhesion and
crawling on the apical surface of intestinal epithelial cells [61]
as well as luminal-to-abluminal neutrophil transepithelial
migration [8]. The engagement of apical ICAM-1 signals to
the actomyosin cytoskeleton in these cells, inducing contrac-
tion and compromising cell barrier function in vivo and in
vitro [61], in a manner comparable to that previously found
in endothelial cells [62, 63]. This suggests that a pathological
accumulation of PMN cells in the lumen of the intestine
may contribute to intestinal barrier dysfunction in response
to infections or during chronic proinflammatory diseases.
It is of note that ICAM-1-blocking antibodies only have an
effect in apical-to-basolateral transepithelial migration and
donot affect basolateral-to-apicalmigration [8].This suggests
that interactions with ICAM-1 probably follow the leukocyte
crossing through JAMs and CD47 basolateral surfaces and
mediate the return of immune cells from the epithelial lumen
towards the parenchyma.
The hyaluronic acid receptor CD44 also belongs to the
immunoglobulin superfamily and participates in a wide
range of pathological diseases [64]. CD44 displays a notable
heterogeneity due to the alternative splicing from the tran-
scription of a single gene, and by the different glycosylation
that each isoform undergoes [64–66]. A blocking antibody
against the CD44 isoform CD44v6 inhibits the detachment
of PMN from the apical membrane domains of polarized
intestinal epithelial cells [67, 68]. Although the molecular
mechanisms mediating the role of CD44v6 in the apical
membrane have not been described in great detail, C44v6
shedding upon PMN interaction seems to be involved.
Specific O-glycosylation of this isoform with sialyl Lewis A
is required for PMN interaction with CD44v6, but this is not
dependent on integrin interactions (Brazil et al., 2013). An
increase in expression of the CD44v6 variant in the apical
membrane domains has been detected in inflamed colonic
mucosa of patients with ulcerative colitis, suggesting a role
for CD44 in mobilizing neutrophils to chronic inflammatory
lesions in the intestinal tract. In contrast, other epithelial
CD44 isoforms, such as CD44v13, which interact with leuko-
cyte 𝛽2 integrins, are basolaterally expressed in polarized
intestinal epithelial cells and so probably mediate other steps
in the haptotactic gradient of the intestinal tissue [69].
Two anti-adhesive molecules are also polarized in the
apical membrane domains of the parenchymal epithe-
lium. The decay-accelerating factor, CD55, and the ecto-5󸀠-
nucleotidase, CD73, are glycosylphosphatidylinositol (GPI)
anchored proteins that are apically expressed in intestinal
epithelial cells [70, 71]. Similar to CD44v6, CD55 has anti-
adhesive properties, although its ligand for infiltrated leuko-
cytes has not been identified yet. CD73 converts AMP to
adenosine, which is anti-inflammatory and, in endothelial
cells at least, reduces leukocyte adhesion and transmigration
[71]. The effect of apical CD73 on leukocyte passage across
epithelial barriers has not been investigated in great detail.
In epithelial cells, CD73 participates in the generation of
adenosine, required for Cl-secretion. Pathological Cl-release
causes secretory diarrea, so a role has been proposed for
CD73 on PMN-mediated Cl-secretion and diarrea in patho-
logical conditions [70]. CD73 also helps metabolize the ATP
secreted by platelets associated with PMN leukocytes that
cross the intestinal barriers in some mucosal diseases, which
promote bacterial clearance in inflammatory conditions [6,
72]. In conclusion, apical CD73 is central to regulate not only
adhesion, but also the effects of immune cells on epithelial
barrier function in a pathological context.
Taken together, the data accumulated so far with respect
to ICAM-1, CD44v6 and CD55 suggest that they orchestrate
the mobilization of immune cells to the luminal side of the
intestine, which determines the intensity, duration and reso-
lution of the inflammatory response. However, as mentioned,
the specific ligands of CD55 and CD44v6 on luminally-
infiltrated leukocytes have not been identified yet and
hence, the molecular machinery in leukocytes involved in
their detachment from epithelial apical membrane domains
remains to be fully elucidated.
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7. Loss of Apicobasal Polarity and Leukocyte
Adhesion to Epithelial Cells
A common feature of most epithelial pathologies is the loss
of apicobasal polarity. Cell death and cancer transformation
are the most evident dysfunctions that cause depolariza-
tion, but the loss of polarity also underlies inflammatory
disorders, such as the inflammatory bowel disease (IBD),
which disrupts cell barrier function in the gut mucosal
epithelium [73, 74]. In hepatocytes, hepatitis C virus infec-
tion disrupts tight junctions and diminishes the canalicular
density in infected livers [75]. Some important diseases
in kidney, such as polycystic kidney disease directly affect
the formation of apical membranes in renal epithelia [76].
Tubular necrosis or autoimmune renal diseases lead to the
malfunction of glomerular filtration by altering epithelial
tight junctions [77]. No studies have been performed so far
on how apicobasal polarity affects the role in the innate
immune response of CD44v6, CD55 or CD73. However,
CD44v isoforms and CD73 are mesenchymal markers and
appear upregulated not only in inflammatory diseases, but
also in malignant transformation of epithelial cells such as
in hepatocellular carcinoma [78, 79], and in cancer stem cells
[80–82].Thus, changes in the expression and/or the polarized
distribution of these plasma membrane proteins could be
involved in the interaction of immune cells with epithelial
cells undergoing de-differentiation events during cancer or
tissue repair (Figure 2).
However, ICAM-1 polarity has receivedmore attention in
polarized hepatic cells. Similar to intestinal epithelial layers,
ICAM-1 appears apically localized in cholangiocytes and
hepatocytes in human tissues from inflammatory diseases
that preserve their parenchymal architecture. In contrast,
ICAM-1 is depolarized in regions with inflammatory damage
and T-cell infiltration, in which parenchymal organization is
clearly affected [7]. Interestingly, in vitro, upon hepatic cell
depolarization, ICAM-1 is dispersed from apical membrane
domains, but remains localized at microvilli at the cell
surface and becomes accessible to immune cells (Figure 2(a)).
Adhesion experiments with human memory T-cells have
shown an inverse relation between the apicobasal polarity and
the ability to interact with lymphocytes of these hepatic cells.
Moreover, loss-of-function experiments by gene silencing or
by using blocking antibodies demonstrated that the increase
of T-cell adhesion to depolarized hepatic cells is mediated by
ICAM-1 exposed upon loss of polarity [7]. Further character-
ization of the molecular bases of ICAM-1 apical localization
indicates that ICAM-1 interaction with the underlying F-
actin scaffold is required for the complete confinement of the
receptor in the apical plasmamembrane domain. In addition,
the analysis of the dynamics of photoactivatable ICAM-1-
GFP protein has shown that ICAM-1 follows an indirect
route of transport toward the apical membrane domain:
ICAM-1 can reach the basolateral membrane of polarized
hepatic cells, but is rapidly redirected to the apical domains,
probably by transcytosis [7]. Thus, polarized, functional
hepatic cells have mechanisms, beyond the regulation of
protein expression, for depleting ICAM-1 from basolateral
membrane domains potentially exposed to hepatic vessels
and immune cells. It is of note that, since columnar epithelial
cells also confine ICAM-1 in apical membrane domains, loss
of apicobasal polarity may have a similar effect on leukocyte-
epithelial adhesion, although this remains to be investigated
(Figure 2(b)).
The intracellular vesicular trafficking in these polarized
cells seems to be important for limiting the accesibility of
these receptors to immune cells and thereby their adhesion,
at least in vitro. Presumably, other apically polarized receptors
involved in leukocyte adhesion, which also interact with the
submembranal actin cytoskeleton, such as CD44 isoforms,
should be more exposed to parenchymal immune cells upon
loss of apicobasal polarity caused by cell transformation,
damage or infection, and thus, may modulate leukocyte
adhesion to those cells that specifically lose their shape
within the epithelial barriers. CD44 and ICAM-1 both inter-
act in their cytoplasmic segments with the ezrin-radixin-
moesin (ERM) protein subfamily that connects them to
filamentous actin [83, 84]. Long-term stimulation with the
inflammatory cytokine TNF𝛼 activates ERMs in different
cell types [85, 86]. Interestingly, in polarized hepatic cells,
TNF𝛼 preferentially activates ERMs at the basolateral mem-
brane domains, causing an increase in ICAM-1 exposure,
probably by retaining the receptor at the basolateral surface
[7] (Figure 2(a)). The molecular requirements for CD44 and
ICAM-1 interaction with ERM proteins are quite similar, so it
is plausible that inflammatory cytokines may also alter CD44
isoform polarity in different epithelial beds through ERM
activation (Figure 2(b)). Therefore, inflammatory cytokines
may regulate not only the expression of epithelial adhesion
receptors, but also their localization in polarized epithelial
cells. Further research on this issue is required, but these
findings could have important consequences in the tissue
inflammatory response in which infiltrated immune cells
need to discriminate operative from dysfunctional, depolar-
ized epithelial cells (Figure 2).
8. Concluding Remarks
In this review we have presented evidence of an essential role
for epithelial apicobasal polarity in generating a chemotactic
andhaptotactic gradient for leukocytes in specific tissues con-
taining parenchymal epithelial layers. This evidence comes
from studies of the secretion of several chemokines and the
polarization of a few receptors involved in the epithelial–
leukocyte interaction. Therefore, a major challenge in the
near future will be the systematic analysis of the apical
and basolateral secretome and “surfaceome” of the main
parenchymal cell types. A systems biology approach inte-
grating all this information is likely to reveal the whole set
of molecular cues that leukocytes encounter in the inflamed
parenchyma during their journey after extravasation. On the
other hand, polarized epithelial cells have sophisticated intra-
cellularmachinery for sorting surface proteins to each plasma
membrane domain. Immunologists have begun to pay closer
attention to the endocytic machinery in leukocytes, which
appears to be an important player for the immune response.
It is time to investigate how vesicular trafficking of recep-
tors and soluble molecules in polarized epithelial cells
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Figure 2: Redistribution of surface receptors and soluble chemoattractants upon loss of apicobasal polarity in epithelial cells. (a) In polarized
hepatocytes, ICAM-1 is able to reach the basolateral membrane but is rapidly redirected to the apical membrane domains. Upon hepatic cell
depolarization or in response to persistent stimulation with the inflammatory cytokine TNF𝛼, ICAM-1 and ezrin-radixin-moesin (ERM)
proteins, which connect the receptor to the underlying actin cytoskeleton, are oriented towards the stromal milieu and become accessible to
immune cells and small hepatic vessels [7]. Other apically polarized receptors involved in leukocyte adhesion, which also interact with the
submembranal actin cytoskeleton, such as CD44 isoforms, should be more exposed to parenchymal immune cells upon loss of apicobasal
polarity. (b) Columnar epithelial cells, such as intestinal cells, express on their apicalmembrane key chemokines and lipidmediators, adhesion
receptors and other membrane proteins involved in the mobilization of immune cells to the luminal side of the epithelial barrier during
inflammation. The proinflammatory cytokine IFN𝛾 is central to increase the expression of some of these receptors, namely ICAM-1 [8].
TNF𝛼 may also contribute, for example, by stimulating IL-8 secretion from the basolateral or the apical membrane domains. Following
epithelial pathologies or cell death, epithelial cells acquire a “mesenchymal phenotype” and therefore, it is plausible to speculate about the
loss of polarized distribution of immune cues also in these epithelial cells. However, the relationship between apicobasal polarity and leukocyte
adhesion remains to be investigated in columnar epithelial cells.
8 Mediators of Inflammation
affect the parenchymal inflammatory response. The effect of
inflammatory mediators on this trafficking and, in general,
on epithelial apicobasal polaritymay provide new therapeutic
opportunities for modulating physiological and pathological
inflammation in complex tissues.
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